Company Filing History:
1 out of 1 
1 out of 2 Years Active: 1998
Introduction
Anthony J d'Apice, an accomplished inventor based in Balwyn, Australia, has made significant strides in the field of xenotransplantation. With a strong focus on addressing hyperacute rejection responses in human organs, his innovative work has opened new avenues for medical research and transplantation.
Latest Patents
Anthony holds a patent titled "Mice homozygous for an inactivated α-1,3-galactosyltransferase - Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation." This invention provides materials and methods for effectively removing or neutralizing human pre-formed xenoantibodies, which are critical in the rejection of donor organs. It details how to reduce or eliminate the epitopes recognized by such antibodies, specifically those formed by the enzyme α-1,3 galactosyltransferase. Anthony's patent also includes information about knocking out the α-1,3 galactosyltransferase gene in mammalian cells and embryos, as well as a novel leukemia inhibitory factor (T-LIF) beneficial for maintaining embryonic stem cells and primordial germ cells in culture.
Career Highlights
Throughout his career, Anthony has worked with notable organizations such as Bresatch Limited and St. Vincent's Hospital. His contributions in these settings have been pivotal in advancing medical technology and enhancing patient care.
Collaborations
Anthony has collaborated with esteemed professionals in the field, including Martin J Pearse and Allan J Robins. These partnerships have enriched his research endeavors and facilitated the development of groundbreaking innovations in xenotransplantation.
Conclusion
Anthony J d'Apice's work exemplifies the intersection of innovation and healthcare. His patent, geared towards mitigating hyperacute rejection in xenotransplantation, stands as a testament to his dedication to improving medical outcomes. Through his career and collaborations, Anthony continues to influence the future of transplantation science.